PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 3.2 MILLION PRIVATE PLACEMENT Paris, April 29, 2026, 8am AB Science S.A. (the “Company” or “AB Science”, Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 3.2 million subscribed by a limited number of investors (the “Private Placement”). The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Authority (Autorité des Marchés Financiers – the “AMF”). Use of proceeds The Company intends to use the net proceeds of the Private Placement to finance its ongoing activities, with a focus on the clinical development of the AB8939 program. This transaction strengthens the Company’s cash position and enables it to cover its financing needs beyond the next...

We hereby provide Consolidated and Company’s financial statements of AB Kauno Energija (company code 235014830) for the year 2025, prepared according to the International Financial Reporting Standards accredited for use in European Union, herewith Consolidated Annual Report and Conclusion of Independent Auditor, approved by the General Meeting of Shareholders. Above mentioned documents also can be found on Company’s website http://www.kaunoenergija.lt. Loreta Miliauskienė, Head of the Economic Department, l.miliauskiene@kaunoenergija.ltAttachmentsabkaunoenergija-2025-12-31-enKauno Energija Independent auditor’s report_2025

HERZLIYA, Israel, April 28, 2026 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX), a global commerce enablement and payments platform designed to help merchants scale their business by simplifying payments and maximizing loyalty, today announced that it will release its earnings for the first quarter of 2026 on Tuesday, May 12, 2026, before U.S. markets open. Nayax will hold two calls, one in English and one in Hebrew. Nayax CEO and Chairman, Yair Nechmad, will speak alongside Nayax’s Chief Financial Officer, Sagit Manor, and Chief Strategy Officer, Aaron Greenberg. Conference Calls: The conference call in English will be held at: 8:30 a.m. Eastern Time / 3:30 p.m. Israel Time / 5:30 a.m. Pacific Time. The conference call in Hebrew will be held at:9:30 a.m. Eastern Time / 4:30 p.m. Israel time / 6:30 a.m. Pacific Time. For...

SHENZHEN, China, April 29, 2026 (GLOBE NEWSWIRE) — Xunlei Limited (“Xunlei” or the “Company”) (NASDAQ: XNET), a leading technology company providing distributed cloud services in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the Securities and Exchange Commission (the “SEC”) on April 28, 2026. The annual report can be accessed on the Company’s investor relations website at http://ir.xunlei.com or the SEC’s website at www.sec.gov. About Xunlei Founded in 2003, Xunlei Limited (NASDAQ: XNET) is a leading technology company providing distributed cloud services in China. Xunlei provides a wide range of products and services across cloud acceleration and digital entertainment to deliver an efficient, smart and safe internet experience. Contact:Investor RelationsXunlei...

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemestrocel-L for the treatment of chronic low back pain (CLBP) associated with degenerative disc disease has achieved its patient recruitment target. This marks a significant milestone in Mesoblast’s plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration. The placebo-controlled study (MSB-DR004) will follow at least 300 patients randomized to a single intra-discal injection of rexlemestrocel-L or sham control for 12 months. The trial seeks to confirm results from the earlier MSB-DR003 trial where a single...

New AI agents embedded across Sage solutions help organizations move beyond analyzing data to automating workflows and acting on insights with confidence, control and accountability ATLANTA, April 28, 2026 (GLOBE NEWSWIRE) — Sage (FTSE: SGE), the leader in accounting, financial, HR and payroll technology for small and mid-sized businesses, today announced the advancement of AI agents across finance, HR and operations at its flagship event Sage Future, embedding intelligent automation directly into core business systems. These capabilities help teams act on work directly, not just analyze it. Sage is bringing these AI agents directly into the systems that businesses and accountants rely on, automating finance workflows in Sage Intacct, workforce management and payroll in Sage’s HCM solutions, and operational insights in Sage X3....

ROCHESTER, NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) — Syntec Optics Holdings, Inc. (Nasdaq: OPTX) (“Syntec Optics”, “Syntec”, or the “Company”), a leading provider of technology to defense tech and other vibrant end-markets, today announced the pricing of an underwritten public offering of 2,857,142 shares of its common stock at a public offering price of $7.00 per share. H.C. Wainwright & Co. is acting as sole book-running manager for the offering. In addition, the Company granted the underwriter a 30-day option to purchase up to 428,571 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about April 30, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds of the offering are expected to...

BEIJING, April 28, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the registrational Phase III clinical trial of novel BTK inhibitor orelabrutinib for the treatment of systemic lupus erythematosus (SLE). This is a randomized, double-blind, placebo-controlled, multicenter Phase III study evaluating the efficacy and safety of orelabrutinib in patients with SLE, with the SRI-4 response rate at Week 52 as the primary endpoint. The Phase IIb clinical study of orelabrutinib met its primary endpoint, making orelabrutinib the first BTK inhibitor to demonstrate significant efficacy in a Phase II clinical trial for SLE. Under stringent steroid-tapering requirements, orelabrutinib...

Miami, FL, April 28, 2026 (GLOBE NEWSWIRE) — Collective Acquisition Corp. II (the “Company”) announced today the pricing of its initial public offering of 22,000,000 units at a price of $10.00 per unit. The units are expected to be listed on The Nasdaq Stock Market LLC (“Nasdaq”) and begin trading tomorrow, April 29, 2026, under the ticker symbol “CAIIU.” Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed...

VANCOUVER, British Columbia, April 28, 2026 (GLOBE NEWSWIRE) — SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) (“SHARC Energy” or the “Company”) is pleased to announce that, further to its news release dated February 17, 2026 and February 23, 2026, the Company has closed the second-tranche of a non-brokered private placement of unsecured convertible debentures of the Company (each, a “Debenture”) for a principal amount of $300,000 (the “Offering”). This brings total proceeds raised to date to $600,000. The Debentures will bear interest from their issue date at 8.0% per annum calculated annually & paid on maturity and will mature three (3) years following the date of issuance (the “Maturity Date”). The Debentures are unsecured and will rank pari passu in right of payment of principal and interest...